Shanghai Fosun Pharmaceutical Industry Development Co. Ltd. has patented new salts of complement factor B (CFB) inhibitors potentially useful for the treatment of diabetic nephropathy, IgA nephropathy, paroxysmal nocturnal hemoglobinuria, C3 glomerulopathy, atypical hemolytic uremic syndrome and membranous nephropathy.